Combined 18F-NaF/18F-FDG PET/MRI for Detection of Skeletal Metastases
Trial ID or NCT#
NCT00375830
Status
NOT RECRUITING
Purpose
This clinical trial studies the use of sodium fluorine-18 (18F-NaF) plus fluorine-18 (18F) fluorodeoxyglucose (FDG) positron emission tomography (PET)/ whole body magnetic resonance imaging (WBMRI) to detect skeletal metastases in patients with stage III-IV breast cancer or stage II-IV prostate cancer.
Official Title
Combined 18F-NaF/18F-FDG PET/MRI for Detection of Skeletal Metastases
Eligibility Criteria
Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: Yes
Exclusion Criteria:
Investigator(s)
Sanjiv Sam Gambhir, MD, PhD
Robert Herfkens
ShreyasÌýVasanawala, MD/PhD
Radiologist
William R. Brody Professor of Pediatric Radiology and Child Health
Contact us to find out if this trial is right for you.
Contact
CCTO
650-498-7061
View on